Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_assertion type Assertion NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_head.
- NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_assertion description "[Metformin has been used as first-line treatment in patients with type 2 diabetes, and is reported to reduce cancer risk and progression by activating the liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_provenance.
- NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_assertion evidence source_evidence_literature NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_provenance.
- NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_assertion SIO_000772 23526220 NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_provenance.
- NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_assertion wasDerivedFrom befree-20140225 NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_provenance.
- NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_assertion wasGeneratedBy ECO_0000203 NP894713.RAuApa2gKGgAwAXbuWwSkLrtU4KJi2bbvphHon2Tzksqc130_provenance.